Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00733252|
Recruitment Status : Withdrawn (Low interest)
First Posted : August 13, 2008
Last Update Posted : October 2, 2015
RATIONALE: Diagnostic procedures, such as optical coherence tomography, may help find and diagnose lung cancer or precancerous cells.
PURPOSE: This phase I trial is studying how well optical coherence tomography of the airway works in detecting abnormal cells in patients undergoing surgery for lung cancer or lung disease.
|Condition or disease||Intervention/treatment|
|Lung Cancer Malignant Mesothelioma Metastatic Cancer Nonmalignant Neoplasm Precancerous Condition||Procedure: bronchoscopic and lung imaging studies Procedure: diagnostic bronchoscopy Procedure: histopathologic examination Procedure: optical coherence tomography|
- Correlate optical coherence tomography images of the airway with airway histology.
- Develop an imaging technique to detect premalignant airway epithelial changes (carcinoma in situ, dysplasia) to study the transformation process as well as intervene and prevent the development of lung cancer.
OUTLINE: Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery. All imaged areas are marked. The marked areas are then excised and fixed in formalin for histopathologic analysis.
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Optical Coherence Tomography of Human Airways|
|Study Start Date :||April 2008|
|Actual Primary Completion Date :||January 2011|
|Actual Study Completion Date :||February 2011|
Procedure: bronchoscopic and lung imaging studies
- Correlation of optical coherence tomography images of the airway with airway histology [ Time Frame: This study will involve discarded tissue from 10 subjects with pathology specimens over one year. ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00733252
|United States, Ohio|
|Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center|
|Cleveland, Ohio, United States, 44106-5065|
|Principal Investigator:||Rana Hejal, MD||Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center|